Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial

Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The record now presents details for the pralsetinib pre-approval access program for patients with unresectable or metastatic NSCLC, medullary thyroid cancer, or certain other RET-altered tumors. It includes eligibility requirements, dosing information, expanded-access status, and study record dates.
    Difference
    26%
    Check dated 2026-11-09T15:05:53.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-02T16:33:04.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide NIH notice about updates to terminology appears above the unchanged 403 error message.
    Difference
    1%
    Check dated 2026-10-26T16:59:01.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T20:49:30.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The footer’s site revision identifier advances from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-13T03:56:01.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error instead of the expected study content, indicating restricted access to the NCT04204928 record and a generic access-denied page is shown.
    Difference
    14%
    Check dated 2026-09-21T22:25:22.000Z thumbnail image

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.